Catalog No.
Product Name
Application
Product Information
Citations
- Daunorubicinol is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.
- Vc-seco-DUBA is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.
- MC-VC-PABC-Aur0101 is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
- PSMA-617, also know as vipivotide tetraxetan. It is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer.
-
DNA Topoisomerase I inhibitor
CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. - MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-Indibulin is a drug-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
-
protein synthesis inhibitor
MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB. - MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity by using duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-carfilzomib is a drug-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-vinblastine is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
- MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
- MC-VC-PABC-DNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
- Nitro-PDS-Tubulysin M is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS.
-
tubulin polymerization inhibitor
MC-Sq-Cit-PAB-Dolastatin10 is a drug-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB. - PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
- MC-Sq-Cit-PAB-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
-
Microtubule inhibitor
VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates. -
Microtubule inhibitor
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates. - MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker.
- PEG4-aminooxy-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.
- MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.
-
DM1 metabolite
Lys-SMCC-DM1 is the active metabolite of DM1. DM1 is a tubulin inhibitor. -
drug-linker conjugate for ADC
AmPEG6C2-Aur0131 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2. -
drug-linker conjugate for ADC
AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC. -
drug-linker conjugates for ADC
NAMPT inhibitor-linker 2 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. - NAMPT inhibitor-linker 1 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker.
- sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
-
drug-linker conjugate for ADC
mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). mDPR-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. -
drug-linker conjugate for ADC
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC. -
drug-linker conjugate for ADC
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. -
drug-linker conjugate for ADC
Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide Val-Cit-PAB. - Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
-
Drug-Linker Conjugate for ADC
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a linker alongside the potent cytotoxic agent MMAE, enabling targeted delivery to cells expressing the c-Kit receptor. This compound can facilitate the synthesis of NN3201 by conjugating with NN2101 (anti c-Kit), which promotes rapid internalization and effectively disrupts SCF-driven signaling pathways. Consequently, NN3201 demonstrates significant anti-tumor activity in various cancer models, including small cell lung cancer (SCLC) and gastrointestinal stromal tumors (GIST). -
Drug-Linker Conjugates for ADC
Mal-N(Me)-C6-N(Me)-PNU-159682 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound utilizes the Mal-N(Me)-C6-N(Me) linker to selectively deliver the cytotoxic agent PNU-159682 to CD46-expressing cells. Upon entering these cells, the linker is cleaved by cathepsin B, resulting in the release of PNU-159682, which induces DNA damage and apoptosis. Notably, Mal-N(Me)-C6-N(Me)-PNU-159682 demonstrates significant tumor regression in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). -
Drug-linker Conjugates for ADC
MC-VC-PAB-Cyclohexanediamine-Thailanstatin A functions as a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. This compound combines the potent cytotoxic properties of Thailanstatin A with a cleavable linker (MC-vc-PAB), facilitating targeted delivery and release of the drug within cancer cells. It is suitable for ADC synthesis and can be utilized in research focused on targeted cancer therapies and improved therapeutic index. -
Drug-Linker Conjugates for ADC
Tesirine is a pyrrolobenzodiazepine (PBD) dimer used as a payload in antibody-drug conjugates (ADCs), primarily targeting cancer cells. It exhibits remarkable antitumor efficacy through its ability to cross-link DNA at the minor groove, leading to potent cytotoxic effects. Tesirine’s favorable hydrophobicity and improved conjugation properties make it an effective component for developing targeted cancer therapies. Its released warhead, SG3199, demonstrates picomolar activity across various cancer cell lines, highlighting its potential in cancer research and therapeutic applications. -
Drug-Linker Conjugate for ADC
DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a SG3199-based DNA small channel crosslinker combined with a cleavable linker, facilitating targeted delivery of therapeutic agents. This reagent is suitable for the synthesis of ADCs, enabling enhanced efficacy in drug-based cancer therapies and other biomedical research applications. -
Drug-Linker Conjugate for ADC
Puxitatug samrotecan drug-linker is a highly specialized drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound combines a potent topoisomerase I inhibitor with a linker moiety, facilitating the targeted delivery of cytotoxic agents to neoplastic cells. Puxitatug samrotecan drug-linker enables the synthesis of ADCs such as Puxitatug samrotecan, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. This reagent is essential for researchers focusing on innovative cancer therapies and targeted drug delivery systems. -
Drug-Linker Conjugates For ADC
Vat-Cit-PAB-Monomethyl Dolastatin 10 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It utilizes Monomethyl Dolastatin 10, a highly effective tubulin inhibitor, linked through the Vat-Cit-PAB linker to enhance its therapeutic potential. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research and the development of targeted therapies.
